Agreement highlights the potential of biodegradable silica material in demanding drug delivery applications
Bayer has signed an agreement with Finnish drug delivery technology firm DelSiTech under which the German healthcare giant will apply DelSiTech’s Silica Matrix drug delivery platform to a number of its ophthalmology compounds.
Under the terms of the agreement, DelSiTech will receive a number of undisclosed milestone payments following the successful completion of different stages of development, as well as milestone payments and royalties on commercialisation and sales.
Bayer will fund all development and commercialisation costs.
This partnership follows an existing collaboration with Bayer in which DelSiTech's Silica Matrix technology has been evaluated.
'Successful ocular drug delivery is one of the biggest challenges in developing novel drug therapies for ophthalmic diseases,' said Professor Andreas Busch, member of the Executive Committee of Bayer's Pharmaceuticals Division and Head of Drug Discovery.
'This agreement will support our work on innovative treatment options for a range of different eye diseases.'
Dr Lasse Leino, CEO of DelSiTech, said: 'We are very pleased that Bayer has chosen DelSiTech as its technology partner for ophthalmology drug delivery. It illustrates the great potential of biodegradable silica material in demanding drug delivery applications.'